US equities |
MU $1,086.26 ▲+3.89% SNDK $1,726.28 ▲+3.96% NVDA $236.91 ▼-0.97% AMD $644.27 ▼-0.79% SPCX $165.83 ▼-3.54% INTC $113.17 ▲+0.60% TSLA $377.01 ▼-0.96% AAPL $336.73 ▲+0.93%
FinancialContent

Articles published by Regeneron Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
News headline image
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Reports Second Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
News headline image
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ASX REGN TLX
News headline image
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
< Previous 1 2 3 4 5 6 7 8 9 Next >